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Background	  
•  Chronic	   suppurative	   lung	   diseases	   (CSLD)	   in	   children	   are	   important	   causes	   of	   morbidity	   and	   recurrent	   acute	  
exacerbations	  are	  associated	  with	  long	  term	  lung	  function	  decline.1	  
	  
•  Non-­‐typeable	  H.	  inﬂuenzae	  (NTHi)	  and	  S.	  pneumoniae	  are	  commonly	  isolated	  from	  the	  lower	  airways	  of	  both	  children	  
and	  adults	  with	  CSLD.2	  
	  
•  The	  potential	  clinical	  impact	  of	  a	  non-­‐typeable	  Haemophilus	  inﬂuenzae	  (NTHi)	  vaccine	  in	  children	  with	  CSLD	  has	  not	  
been	  investigated.	  	  
•  We	  aimed	  to	  determine	  the	  clinical	  eﬃcacy	  of	  the	  10-­‐valent	  pneumococcal-­‐Protein	  D	  conjugate	  vaccine	  (10vPHiD-­‐CV)	  
in	  children	  aged	  18-­‐months	  to	  <18-­‐years	  with	  CSLD	  (Immunogenicity	  data	  are	  presented	  in	  Poster	  xxx).	  
	  
Primary	  clinical	  objective	  
•  Determine	  the	  eﬃcacy	  of	  10vPHiD-­‐CV	  in	  reducing	  the	  incidence	  of	  acute	  exacerbations	  in	  the	  12-­‐months	  following	  
the	  2nd	  dose	  of	  study	  vaccine.	  
	  
Secondary	  clinical	  objectives	  
•  Determine	  the	  eﬃcacy	  of	  10vPHiD-­‐CV	  in	  reducing	  the	  incidence	  of	  any	  parent/carer-­‐reported	  respiratory	  symptoms	  
in	  the	  12	  months	  following	  the	  second	  dose	  of	  study	  vaccine.	  
	  




•  Multi-­‐centre,	  parallel	  group	  (1:1	  allocation),	  double-­‐blind,	  randomised	  controlled	  trial.	  3	  
	  
•  Children	  received	  2	  doses,	  2-­‐months	  apart	  of	  10vPHiD-­‐CV	  or	  meningococcal-­‐ACYW135	  conjugate	  vaccine	  (Figure	  1).	  	  
	  
•  Inclusion/exclusion	  criteria	  are	  listed	  in	  Box	  1;	  a	  glossary	  of	  terms	  is	  	  provided	  in	  Box	  	  2.	  
	  
•  Children	  underwent	  active	  fortnightly	  surveillance	  for	  acute	  exacerbations,	  respiratory	  symptoms	  and	  antibiotic	  use	  
for	  12-­‐months	  post	  the	  second	  dose	  of	  vaccine.	  	  
•  In	  intention-­‐to-­‐treat	  analyses,	  incidence	  rate	  ratios	  (IRRs)	  were	  calculated	  with	  child-­‐weeks	  at	  risk	  commencing	  14-­‐
days	  post	  the	  second	  vaccine	  dose.	  	  
•  Child	  time	  at	  risk	  was	  calculated	  in	  weeks	  for	  exacerbations	  and	  antibiotic	  use	  and	  fortnights	  were	  the	  denominator	  
for	  parent/carer	  reported	  respiratory	  symptoms.	  
	  
•  Subanalyses	  were	  performed	  	  to	  determine	  the	  incidence	  of	  clinical	  endpoints	  following	  the	  ﬁrst	  dose	  of	  vaccine.	  
Results	  
•  The	  required	  sample	  size	  of	  206	  children	  was	  not	  achieved	  given	  recruitment	  diﬃculties.	  
	  
•  879	  children	  were	  screened	  and	  62	  enrolled;	  481	  (55%)	  were	  ineligible,	  257	  (29%)	  refused	  &	  79	  (9%)	  
were	  not	  enrolled	  for	  other	  reasons.	  One	  child	  was	  unblinded	  	  &	  withdrawn	  following	  a	  serious	  
adverse	  event	  unrelated	  to	  study	  vaccine	  &	  excluded	  from	  the	  analysis.	  
	  
•  The	  mean	  age	  of	  enrolled	  children	  7.0-­‐years	  (95%CI	  6.0,	  7.9);	  53.5%	  were	  male	  (Table	  1).	  There	  were	  
no	  diﬀerences	  in	  gender	  and	  age	  between	  children	  who	  were	  and	  were	  not	  enrolled.	  
	  
•  Baseline	  characteristics	  are	  provided	  in	  Table	  1	  and	  incidence	  rates	  of	  clinical	  endpoints	  are	  presented	  
in	  Table	  2.	  
Discussion	  
•  We	  have	  identiﬁed	  a	  potentially	  important	  role	  for	  the	  10vPHiD-­‐CV	  in	  the	  clinical	  management	  of	  
children	  with	  CSLD.	  
•  While	  the	  sample	  size	  was	  inadequate	  for	  the	  primary	  endpoint,	  children	  who	  received	  10vPHiD-­‐CV	  
required	  less	  courses	  of	  antibiotics	  and	  experienced	  less	  time	  with	  respiratory	  symptoms	  than	  those	  
in	  the	  control	  group.	  
•  Our	  clinical	  data	  are	  supported	  by	  the	  mucosal	  and	  systemic	  antibody	  responses	  to	  vaccine	  
presented	  in	  Poster	  xx.	  
	  
•  Larger	  trials,	  involving	  multiple	  recruitment	  sites,	  are	  now	  required	  to	  conﬁrm	  our	  ﬁndings.	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Inclusion	  Criteria	   Exclusion	  Criteria	  
•  Child	  aged	  ≥	  18	  months	  and	  <	  18	  years	  with	  CSLD,	  bronchiectasis	  or	  recurrent	  
PBB	  (Box	  2)	  	  
•  Chronic	   lung	   condition,	   including	   cystic	   ﬁbrosis,	   other	   than	   those	   under	  
investigation	  in	  this	  study	  
•  At	  least	  2	  respiratory	  exacerbations	  within	  the	  18-­‐months	  prior	  to	  enrolment	  
	  
•  Prior	   vaccination	  with	  PHiD-­‐CV	  vaccine;	   contraindication	   to	  PHiD-­‐CV	  and/or	  
quadrivalent	  (ACYW135)	  meningococcal	  	  conjugate	  vaccine	  
•  Age-­‐appropriately	  immunised	  with	  PCV7	  and/or	  PCV13	   •  Known	  hypersensitivity	  to	  any	  component	  of	  the	  vaccines,	  including	  latex	  	  
•  A	   prior	   dose	   of	   Pneumovax	   23	   was	   permitted.	  At	   least	   2-­‐months	   post	   the	  
dose	  of	  non-­‐study	  pneumococcal	  vaccine	  was	  required	  prior	  to	  enrolment	  
•  Conﬁrmed	  or	   suspected	   immunosuppressive	   condition	  or	   immunodeﬁciency	  
disorder	   that	   may	   be	   expected	   to	   interfere	   with	   immune	   response	   to	  
vaccination	  	  
•  If	  vaccinated	  with	  a	  meningococcal	  C	  conjugate	  vaccine,	  a	  period	  of	  at	  least	  6	  
months	  post	  vaccination	  was	  required	  prior	  to	  enrolment.	  	  
•  Current	  (or	  within	  90	  days	  prior	  to	  receiving	  study	  vaccine)	  or	  planned	  (during	  
the	   active	   study	   period)	   immunosuppressive	   therapy,	   including	   systemic	  
corticosteroids	  (≥14	  days).	  Inhaled	  steroids	  were	  allowed	  	  
•  Negative	  urine	  pregnancy	  test	  if	  post-­‐menarcheal	  female	  
	  
•  Administration	   of	   immunoglobulins	   and/or	   blood	   products	   within	   90	   days	  
prior	   to	   receiving	   study	  vaccine,	  or	  planned	  administration	  of	   such	  products	  
during	  the	  study	  period	  	  
•  Provision	   of	   written	   informed	   consent	   from	   parent/guardian	   (assent	   from	  
child	  as	  per	  local	  HREC	  requirements)	  
•  Active	  participation	  in	  a	  clinical	  trial	  of	  another	  investigational	  drug/vaccine	  or	  
interventional	  therapy	  
•  Parent/child	  willing	  and	  able	  to	  meet	  the	  requirements	  of	  the	  protocol	   •  Acute	   disease	   at	   the	   time	   of	   enrolment.	   Acute	   disease	   was	   deﬁned	   as	   a	  
moderate	   or	   severe	   illness	   with	   or	   without	   fever	   (axillary	   temperature	   ≥	  
38.0oC)	  at	  the	  time	  of	  enrolment.	  A	  temperature	  greater	  than	  or	  equal	  to	  this	  
cut-­‐oﬀ	   warrants	   deferral	   of	   the	   vaccination	   pending	   recovery	   of	   the	  
participant	  	  
•  Not	  planning	  to	  move	  from	  the	  study	  area	  in	  the	  14	  months	  post	  enrolment	   •  Other	   medical/psychosocial	   condition	   that	   the	   investigators	   considered	  
warranted	   exclusion	   from	   the	   trial	   to	   prevent	   potential	   harm/risk	   to	   the	  
subject	  or	  may	  adversely	  aﬀect	  study	  outcomes	  
Term	   Deﬁnition	  
Chronic	  suppurative	  lung	  disease	  
(CSLD)	  
A	  clinical	  syndrome	  where	  there	  are	  signs/symptoms	  indicating	  chronic	  endobronchial	  
suppuration	  with	  or	  without	  HRCT	  evidence	  of	  radiological	  bronchiectasis.	  This	  includes	  
chronic	  wet	  or	  productive	  cough	  and	  either	  failure	  of	  cough	  to	  respond	  to	  oral	  antibiotics	  or	  
presence	  of	  additional	  respiratory	  symptoms	  or	  signs	  (eg.	  clubbing,	  chest	  wall	  deformity	  or	  
crackles)	  
Bronchiectasis	   Features	  of	  CSLD	  plus	  conﬁrmed	  bronchiectasis	  by	  chest	  HRCT	  scan	  in	  last	  5	  years	  
	  
Recurrent	  protracted	  bacterial	  
bronchitis	  (PBB)	  
The	  presence	  of	  isolated	  chronic	  (>4	  weeks)	  of	  wet/moist	  cough	  that	  resolves	  with	  antibiotics	  
in	   the	   absence	   of	   pointers	   suggestive	   of	   an	   alternative	   speciﬁc	   cause	   of	   cough.	   3	   prior	  
episodes	  deﬁned	  recurrent	  PBB.	  
Respiratory	  exacerbation	   An	  increase	  in	  sputum	  volume	  or	  purulence	  or	  ≥	  3-­‐days	  of	  change	  in	  cough	  (>20%	  increase	  in	  
cough	   score	   or	   type	   [dry	   to	   wet]).	   A	   cough	   must	   have	   been	   wet	   to	   be	   considered	   an	  
exacerbation.	  The	   ‘baseline-­‐state’	   for	  each	  child	  was	  established	  at	  enrolment,	  prior	   to	  any	  
exacerbations.	  This	   consisted	   of	   a	   combination	   of	   symptoms	   [daily	   cough	   (yes/no),	   cough	  
quality	   (wet/dry/none),	   cough	   score	   averaged	  over	   2	  days	   and	   signs	   [sputum	  colour	   (if	   any	  
present),	  crackles	  on	  chest	  auscultation].	  	  
Respiratory	  symptoms	  under	  
surveillance	  
cough,	  sputum	  production,	  sputum	  colour,	  rhinorrhoea,	  fever,	  wheeze,	  shortness	  of	  breath,	  
tachypnoea,	  dyspnoea,	  stridor,	  headache,	  sore	  throat,	  earache.	  
Endpoint	   PHiD-­‐CV	  	  
N	  =	  	  31	  
	  MenACYW135	  	  
N	  =	  30	  
n/time	  at	  risk	  
(IR)	  
n/time	  at	  risk	  
(IR)	  
	  
IRR	  (95%CI)	   P-­‐value	  
Exacerbations	  post	  dose	  2	   71	  /	  1698	  weeks	  
(4.2	  /	  100	  weeks)	  
73	  /	  1549	  week	  
(4.7	  /	  100	  weeks)	  
0.88	  (0.64	  –	  1.23)	   0.237	  
Exacerbations	  post	  dose	  1	   106	  /	  1877	  weeks	  
(5.6	  /	  100	  weeks)	  
106	  /	  1637	  weeks	  
(6.5	  /	  100	  weeks)	  
0.87	  (0.67	  –	  1.14)	   0.160	  
Fortnights	  with	  respiratory	  symptoms	  post	  dose	  2	   213/849	  fortnights	  
(25/100	  fortnights)	  
260	  /	  775	  fortnights	  
(36/100	  fortnights)	  
0.75	  (0.62	  –	  0.90)	   0.002	  
Fortnights	  with	  respiratory	  symptoms	  post	  dose	  1	   266	  /	  939	  fortnights	  
(28/100	  fortnights)	  
320	  /	  818	  fortnights	  
(39/100	  fortnights)	  
0.72	  (0.62	  –	  0.85)	   <0.001	  
Antibiotic	  courses	  	  <	  14	  days	  post	  dose	  2	   77	  /	  1692	  weeks	  
(4.5/100	  weeks)	  
94	  /	  1528	  weeks	  
(6.2/100	  weeks)	  
0.74	  (0.55	  –	  0.99)	   0.025	  
Antibiotic	  courses	  	  <	  14	  days	  post	  dose	  1	   109	  /	  2094	  weeks	  
(5.2/100	  weeks)	  
123	  /	  1961	  weeks	  
(6.3/100	  weeks)	  
0.83	  (0.64	  –	  1.07)	   0.078	  
Antibiotic	  courses	  <	  28	  days	  post	  dose	  2	   92	  /	  1657	  weeks	  
(5.5/100	  weeks)	  
102	  /	  1515	  weeks	  
(6.7	  /	  100	  weeks)	  
0.82	  (0.62	  –	  1.09)	   0.091	  




0.90	  (0.71	  –	  1.15)	   0.204	  
Antibiotics	  of	  any	  duration	  post	  dose	  2	   92	  /	  1647	  weeks	  
(6.8	  /	  100	  weeks)	  
102	  /	  1505	  weeks	  
(5.6	  /	  100	  weeks)	  
0.82	  (0.62	  –	  1.09)	   0.086	  
Antibiotics	  of	  any	  duration	  post	  dose	  1	  
	  
127	  /	  2035	  weeks	  
(6.9	  /	  100	  weeks)	  
133	  /	  1926	  weeks	  
(6.2	  /	  100	  weeks)	  
0.90	  (0.71	  –	  1.15)	   0.207	  
Child	  characteristic	   PHiD-­‐CV	  	  
n	  =	  31	  
	  MenACYW135	  	  
n	  =	  30	  
	  p	  value	  
Age	  group	  
<	  6	  years	  









































































Mean	  #	  parent	  reported	  respiratory	  exacerbations	  in	  past	  18	  
months	  (95%CI)	  
7.7	  (6.1	  –	  9.4)	   8.2	  (6.1	  –	  10.2)	   0.725	  
Box	  2:	  Glossary	  of	  study	  deﬁnitions	  
Figure	  1.	  Overview	  of	  trial	  design	  
Box	  1.	  Trial	  eligibility	  criteria	  
Table	  1.	  Baseline	  characteristics	  of	  CHiRRP	  children	  
Table	  2:	  Incidence	  rates	  (IR)	  /	  child	  time	  at	  risk	  and	  Incidence	  Rate	  Ratios	  (IRR)	  for	  clinical	  endpoints	  
